Hims & Hers hasn’t escaped a tumultuous start to the year either. The company’s stock boomed in 2024, boosted in part by ...

The versions affected are called compounded medications, which have the same active ingredients as the name brands. The ...

Shares in telehealth business Hims & Hers Health (HIMS) dropped over 6% today after reports that it and peers are marketing ...

The rapid rise of GLP-1 weight-loss drugs has come with a raucous side show—a wave of copycat drugs unbound by drug patents. The knockoff surge was led by Hims & Hers Health, the telehealth firm that ...

Hims & Hers Health, Inc. stock faces volatility after an FDA halt on its GLP-1 drug. Click here to find out why HIMS stock is ...

San Francisco-based Hims & Hers is shutting down Apostrophe, a Bay Area dermatology telehealth company that it bought for ...

After years of weight loss drug shortages, the FDA is saying there’s now an adequate supply for most medications and they ...

Hims & Hers' lower-priced injectable semaglutide promoted during the Super Bowl has led to some patients receiving the more affordable metformin inste ...

Following Hims & Hers’ Super Bowl ad for its weight loss product, a debate has emerged over the safety of compounded GLP-1s for patients. Compounded GLP-1s are custom-made by compounding ...

Shares of Hims & Hers fell more than 27% to $37.34 in morning ... "The reality in the market is the medication remains in short supply, as we see in continuing shortage reports from our members ...

Hims & Hers Health, Inc. operates a telehealth platform ... It also provides prescription medication on a recurring basis and ongoing care from healthcare providers; and over-the-counter drug ...